Restrictions to thrombolytic therapy for stroke—recommended only up to 4.5 h after onset and in those under 80 years of age—limit its use. Results from a recent trial support expansion of both the inclusion criteria and the time window for thrombolytic therapy, but further research is needed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The dual roles of autophagy and the GPCRs-mediating autophagy signaling pathway after cerebral ischemic stroke
Molecular Brain Open Access 02 February 2022
-
Therapeutic Antibodies in Stroke
Translational Stroke Research Open Access 16 August 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Donnan, G. A., Fisher, M., Macleod, M. & Davis, S. M. Stroke. Lancet 371, 1612–1623 (2008).
Davis, S. M. & Donnan, G. A. Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 366, 1914–1922 (2012).
Whiteley, W., Lindley, R., Wardlaw, J. & Sandercock, P. Third international stroke trial. Int. J. Stroke 1, 172–176 (2006).
IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379, 2352–2363 (2012).
Sandercock, P., Lindley, R., Wardlaw, J., Whiteley, W. & Murray, G. Statistical analysis plan for the third international stroke trial (IST-3); part of a 'thread' of reports of the trial. Int. J. Stroke 7, 186–187 (2012).
Wardlaw, J. M. et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379, 2364–2372 (2012).
Medcalf, R. L. & Davis, S. M. Plasminogen activation and thrombolysis for ischemic stroke. Int. J. Stroke 7, 419–425 (2012).
Ma, H. et al. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int. J. Stroke 7, 74–80 (2012).
Parsons, M. et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N. Engl. J. Med. 366, 1099–1107 (2012).
Fiebach, J. B. et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 43, 1561–1566 (2012).
Acknowledgements
Our research in this area is supported by a programme grant from the Australian National Medical Research Council and the Commonwealth Scientific and Industrial Research Organization. Support is also received from the Victorian Government Operational Infrastructure Scheme.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. A. Donnan and S. M. Davis are co-Principle Investigators of the EXTEND trial for which Boehringer Ingelheim provide the drug and placebo, but no financial support.
Rights and permissions
About this article
Cite this article
Donnan, G., Davis, S. Expanded indications for stroke thrombolysis—what next?. Nat Rev Neurol 8, 482–483 (2012). https://doi.org/10.1038/nrneurol.2012.151
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.151
This article is cited by
-
The dual roles of autophagy and the GPCRs-mediating autophagy signaling pathway after cerebral ischemic stroke
Molecular Brain (2022)
-
Therapeutic Antibodies in Stroke
Translational Stroke Research (2013)
